ClinicalTrials.gg
TerminatedNCT06274359Updated Aug 28, 2026Results posted

Digital Storytelling to Reduce Pediatric Influenza Vaccination Disparities

An interventional study of Digital storytelling in Influenza, sponsored by Denver Health and Hospital Authority. Terminated at 2 sites in United States. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Denver Health and Hospital Authority · Not applicable, Interventional, and Prevention

Why this study was terminated
National Institutes of Health terminated funding on March 10, 2025.
Phase
Not applicable
Study type
Interventional
Enrollment
398
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

While the COVID-19 pandemic has highlighted health disparities, Black children have unduly suffered and died from seasonal influenza for decades. Through sustained partnership with Black community stakeholders, novel community-engaged research methods, and an innovative intervention approach, this proposal will explore, develop, and test a Digital Storytelling intervention to reduce influenza vaccination disparities in Black children aged 6 months to 5 years. This project will advance our understanding of engagement methods and interventions that improve health equity and serve as a model for future work to address vaccination disparities, ensuring all individuals have the chance to fulfill their potential free of preventable diseases.

Read the detailed description

Study Aim: To (a) assess acceptability, appropriateness, and feasibility of the digital storytelling (DST) intervention, and (b) estimate a pilot effect size of the intervention, via a Pragmatic Trial in 2 clinics in historically Black neighborhoods.

Overview: A pilot pragmatic trial of a DST intervention in caregivers of children 6 mo. to 5 yrs. (n = 200) receiving care at two clinics in historically Black neighborhoods in Denver, CO during one influenza season (10/1/24-3/30/25), assessing pragmatic outcomes and pilot effectiveness with mixed methods.

Setting \& Design: The investigators will pilot the intervention at 2 Denver Health primary care clinics in historically Black neighborhoods. These clinics serve >3,000 empaneled Black children and provided >6,000 influenza vaccines to children in 2020-21. Caregivers will be eligible if their child is empaneled (i.e., had 1 well child visit in last 18 months), will be 6 months to 5 years old during the upcoming influenza season (10/1 to 3/30), and has no medical contraindications to vaccination. The investigators will exclude caregivers whose first language is not English, as digital stories will be narrated in English, or are younger than 18 years. A research assistant will recruit caregiver-child dyads from May 1, 2024 to September 30, 2024 in clinic waiting rooms. Caregivers will complete a survey with demographic and vaccine hesitancy items and provide their cell phone number and e-mail address for intervention purposes.

Intervention Description: While this work is highly emergent in nature and exact implementation details are subject to stakeholder refinement, the investigators anticipate the following structure. On October 1st, dyads will be randomized to intervention or control groups (1:1 ratio). Intervention caregivers will receive a series of 6 monthly texts with embedded digital stories and accompanying health messaging. Control caregivers will receive usual care.

Outcomes: Our primary aim will be child influenza vaccination status, extracted from our electronic health record (EHR) at season's end (March 30, 2025). Caregivers assigned to the intervention group (n = 100) will receive a follow-up survey with validated measures assessing their perceptions of intervention feasibility, acceptability, and appropriateness.

Covariates: Caregiver independent variables will include age, sex (as a biological variable), education, income, race, ethnicity, insurance status, and scaled vaccine hesitancy score (range: 0-100, with 0 indicating not at all hesitant). The investigators will assess caregivers' perceptions of DST feasibility, appropriateness, and acceptability with validated questions on a 5-point Likert scale, which read at a 5th grade level. Child-level variables will include age, sex (as a biological variable), race, and ethnicity. To estimate pilot effectiveness for future power calculations, our primary outcome will be child vaccination status at season's end (March 30th), defined in a binary manner (receipt of ≥ 1 dose by season's end versus unvaccinated). The investigators chose this definition as our pilot data found parental vaccine hesitancy increased a child's risk of influenza non-vaccination but did not increase their risk of partial vaccination (vs. full).

Analyses, Sample Size, \& Calculations: The investigators will calculate descriptive statistics of caregivers' demographics and vaccine hesitancy scores. For our primary outcome of pilot effectiveness, the investigators will use an intention-to-treat approach comparing the proportion of children of caregivers randomized to digital stories versus literacy videos who received 1 or more vaccine dose by season's end. The investigators will fit univariable and multivariable logistic regression models to explore associations with caregiver demographics and parental vaccine hesitancy scores. To address instances of video non-viewing, the investigators will repeat these analyses between caregivers whose unique Digital Story links were accessed - i.e., presumably viewed - and caregivers in the control group.

The investigators will then describe intervention caregivers' perceptions of feasibility, acceptability, and appropriateness; as set cut points for acceptability and appropriateness do not yet exist, the investigators plan to use ≥ 70% agreement as with prior work by our group. Using these cut points, the investigators will fit univariable and multivariable logistic regression models to estimate the association between covariates (e.g., demographics, vaccine hesitancy score) and whether a caregiver perceived the intervention as feasible, acceptable, or appropriate.

The investigators performed sample size calculations based on the precision with which the investigators could estimate the treatment effect, as measured by the difference in proportion vaccinating between intervention and control arms. The investigators hypothesize our estimated pilot effect size will be ≥ 0.10, or modest for a vaccination trial. With n = 200, the investigators expect to attain a margin of error (equal to one half of the width of a 95% confidence interval) for the estimated treatment effect of approximately 0.14). All analyses will be performed in R.

SA3.5. Limitations \& Alternative Approaches: (1) Poor recruitment. The investigators collected pilot data in the same clinic and 2 others from 255 caregivers of 2 year-olds in 6 months. By extending inclusion criteria to ages 6 months to 5 years, the investigators are confident the investigators can recruit 200 dyads. If necessary, the work will continue during a second influenza season (10/1/2025 - 3/31/2026) to ensure the investigators meet recruitment goals. (2) Poor perceived acceptability, appropriateness, or feasibility. If our analyses suggest the investigators need to improve intervention feasibility, acceptability, or appropriateness, the investigators will work with community and clinical stakeholders to iteratively modify and pilot-test the adapted intervention.

02

Conditions studied

  • Influenza

Browse trials for

Keywords

  • influenza
  • digital storytelling
  • children
  • health disparities
03

In context

Influenza, Human

2,356 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

This study's enrollment of 398 is above the median of 227 across 1,957 interventional studies indexed under Influenza, Human.

Browse Influenza, Human studies →

Lead sponsor

Denver Health and Hospital Authority is the lead sponsor of 84 studies on the registry; 4 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Caregivers of a child who is empaneled at Denver Health (e.g. had 1 well child visit in last 18 months)
  • Child will be aged 6 months to 5 years during the influenza season in which the trial will be conducted (season 1: 10/1/24-3/31/25; season 2 (if needed): 10/1/25-3/31/26)
  • Child has no medical to vaccination (e.g., severe allergy to one of the vaccine ingredients, history of Guillan-Barre Syndrome)

Exclusion criteria

Exclusion Criteria:

- Caregivers whose first language is not English

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
398 participants (actual)

Study arms

  • Experimental
    Digital storytelling group

    Caregivers will receive a series of digital stories by text message designed to increase influenza vaccine confidence.

    Behavioral: Digital storytelling

  • No intervention
    Control group

    Caregivers will receive standard care.

Interventions

  • BehavioralDigital storytelling

    Caregivers will receive text messages with embedded digital stories and messaging to encourage influenza vaccination.

06

What researchers measure

Primary outcomes

  1. Child Participant Vaccination During the 2024-2025 Influenza Season

    Child participant receipt of 1 or more doses of influenza vaccine from the date influenza vaccines were available at study sites (9/16/24) through the last date of the study period (3/31/25).

    Time frame: 196 Days

Secondary outcomes

  1. Digital Story Reach

    Percentage of caregivers assigned to intervention who watched one or more digital stories from the date the first story was sent out (10/1/24) through the study period end (3/31/25).

    Time frame: 181 days

07

Results

Posted Aug 28, 2026

Participant flow

Dyads - caregivers and children (6 months to 5 years old) from two safety-net clinics in historically Black neighborhoods in Denver, Colorado - were recruited between August 2nd, 2024 and September 15th, 2024 and followed through March 31, 2025, after which time vaccination status was extracted for children.

Participant flow — Overall Study
MilestoneIntervention: ChildrenUsual Care: ChildrenIntervention: CaregiversUsual Care: Caregivers
Started10010098100
Completed10010098100
Not completed0000

Outcome measures

PrimaryChild Participant Vaccination During the 2024-2025 Influenza Season

Child participant receipt of 1 or more doses of influenza vaccine from the date influenza vaccines were available at study sites (9/16/24) through the last date of the study period (3/31/25).

Time frame:
196 Days
Reported as:
Number · Participants with 1 or more vaccinations
Child Participant Vaccination During the 2024-2025 Influenza Season
Participants with 1 or more vaccinationsIntervention: ChildrenUsual Care: Children
Child Participant Vaccination During the 2024-2025 Influenza Season4128
SecondaryDigital Story Reach

Percentage of caregivers assigned to intervention who watched one or more digital stories from the date the first story was sent out (10/1/24) through the study period end (3/31/25).

Time frame:
181 days
Reported as:
Count of participants · Participants
Digital Story Reach
ParticipantsIntervention: CaregiversUsual Care: Caregivers
Digital Story Reach70

Adverse events

Collected over Throughout the 2024-2025 influenza season at participating clinics, up to 196 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intervention: Children0/100 (0%)0/100 (0%)0/100 (0%)
Usual Care: Children0/100 (0%)0/100 (0%)0/100 (0%)
Intervention: Caregivers0/98 (0%)0/98 (0%)0/98 (0%)
Usual Care: Caregivers0/100 (0%)0/100 (0%)0/100 (0%)

Baseline characteristics

There are no differences here versus in the participant flow.

Age, Customized
Age, Customized(Years)Intervention: ChildrenUsual Care: ChildrenIntervention: CaregiversUsual Care: CaregiversTotal
Age in years of participating caregivers——30.8 ± 7.630.2 ± 7.430.5 ± 7.5
Age, Customized
Age, Customized(Months)Intervention: ChildrenUsual Care: ChildrenIntervention: CaregiversUsual Care: CaregiversTotal
Age in months of participating children28.1 ± 15.430.0 ± 16.7——29.1 ± 16.1
Sex: Female, Male
Sex: Female, Male(Participants)Intervention: ChildrenUsual Care: ChildrenIntervention: CaregiversUsual Care: CaregiversTotal
Female47579091285
Male534389113
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Intervention: ChildrenUsual Care: ChildrenIntervention: CaregiversUsual Care: CaregiversTotal
Hispanic or Latino47434443177
Not Hispanic or Latino49525457212
Unknown or Not Reported45009
Race/Ethnicity, customized
Race/Ethnicity, customized(Participants)Intervention: ChildrenUsual Care: ChildrenIntervention: CaregiversUsual Care: CaregiversTotal
Black or African American38393443154
Another Race and or Ethnicity58566457235
Missing or Prefer Not to Answer45009
08

Study locations

2 sites
  • Denver Health Eastside Clinic
    Denver, Colorado 80205, United States
  • Denver Health Park Hill Clinic
    Denver, Colorado 80207, United States
09

References and documents

Publications

  • Weiner BJ, Lewis CC, Stanick C, Powell BJ, Dorsey CN, Clary AS, Boynton MH, Halko H. Psychometric assessment of three newly developed implementation outcome measures. Implement Sci. 2017 Aug 29;12(1):108. doi: 10.1186/s13012-017-0635-3. PubMed 28851459 ↗
  • Williams JTB, Kurlandsky K, Stein AB, Bharadwaj N, Hambidge SJ, Pereira RI, O'Leary SC, Johnson D, O'Leary ST. Narrative Reminder Recall to Improve Pediatric Influenza Vaccination: A Pilot Randomized Clinical Trial. JAMA Netw Open. 2026 Jan 2;9(1):e2552149. doi: 10.1001/jamanetworkopen.2025.52149. PubMed 41493783 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Only aggregate data will be shared

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Mar 2025, 7 months.

Results were first posted in Aug 2026, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2024
First posted
Feb 23, 2024
StartActual
Aug 2, 2024
Primary completionActual
Mar 31, 2025
CompletionActual
Mar 31, 2025
Results first posted
Aug 28, 2026
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06274359
Lead sponsor
Denver Health and Hospital Authority
Responsible party
Sponsor
First posted
Feb 23, 2024
Start date
Aug 2, 2024
Primary completion
Mar 31, 2025
Completion
Mar 31, 2025
Results posted
Aug 28, 2026
Last update
Aug 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion